Optimer Pharmaceuticals Stock Price, News & Analysis (NASDAQ:OPTR)

Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Optimer Pharmaceuticals (NASDAQ:OPTR)

Optimer Pharmaceuticals logoOptimer Pharmaceuticals, Inc. (Optimer) is a biopharmaceutical company focused on developing and commercializing hospital specialty products. The Company's development is focused on products that treat gastrointestinal infections and related diseases. Its two products OPT-822/821 and CEM-101 (OP-1068) are in clinical development. Optimer's products include Fidaxomicin and Solithromycin under anti-infectives, and OPT-822/821 under other therapeutic areas. In January 2011, its majority owned subsidiary, Optimer Biotechnology, Inc. (OBI) conducted a Phase 2/3 clinical, trial to evaluate OPT-822/821for the treatment of metastatic breast cancer. On May 27, 2011, the United States Food and Drug Administration (FDA) approved DIFICID(fidaxomicin) tablets, its antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). In October 2013, Cubist Pharmaceuticals, Inc announced that it has completed its acquisition of Optimer Pharmaceuticals, Inc.

Receive OPTR News and Ratings via Email

Sign-up to receive the latest news and ratings for OPTR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biopharmaceuticals
Sub-IndustryPharmaceuticals
SectorBiopharmaceuticals
SymbolNASDAQ:OPTR
CUSIP68401H10
Phone+1-201-3338819

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A

Optimer Pharmaceuticals (NASDAQ:OPTR) Frequently Asked Questions

What is Optimer Pharmaceuticals' stock symbol?

Optimer Pharmaceuticals trades on the NASDAQ under the ticker symbol "OPTR."

Who are some of Optimer Pharmaceuticals' key competitors?

How do I buy Optimer Pharmaceuticals stock?

Shares of Optimer Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Optimer Pharmaceuticals?

Optimer Pharmaceuticals' mailing address is 101 Hudson St Ste 3501, JERSEY CITY, NJ 07302-3915, United States. The biopharmaceutical company can be reached via phone at +1-201-3338819.


MarketBeat Community Rating for Optimer Pharmaceuticals (OPTR)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  131 (Vote Outperform)
Underperform Votes:  67 (Vote Underperform)
Total Votes:  198
MarketBeat's community ratings are surveys of what our community members think about Optimer Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Optimer Pharmaceuticals (NASDAQ:OPTR) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

Optimer Pharmaceuticals (NASDAQ:OPTR) Earnings History and Estimates Chart

Earnings by Quarter for Optimer Pharmaceuticals (NASDAQ:OPTR)

Optimer Pharmaceuticals (NASDAQ OPTR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2013Q2 2013($0.62)($0.55)$21.31 million$20.10 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.46)($0.65)$21.09 million$19.43 millionViewN/AView Earnings Details
2/28/2013Q4 2012($0.57)$0.02$18.05 million$19.50 millionViewN/AView Earnings Details
11/1/2012Q312($0.63)($0.56)$16.03 million$17.89 millionViewN/AView Earnings Details
7/31/2012($0.07)($0.01)ViewN/AView Earnings Details
5/10/2012($0.40)($0.23)ViewN/AView Earnings Details
3/7/2012$0.51$0.29ViewN/AView Earnings Details
11/3/2011($0.51)($0.57)ViewN/AView Earnings Details
8/4/2011($0.39)($0.52)ViewN/AView Earnings Details
5/5/2011($0.30)$1.04ViewN/AView Earnings Details
3/10/2011($0.33)($0.31)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Optimer Pharmaceuticals (NASDAQ:OPTR) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Optimer Pharmaceuticals (NASDAQ:OPTR)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Optimer Pharmaceuticals (NASDAQ OPTR) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Optimer Pharmaceuticals (NASDAQ:OPTR)

Optimer Pharmaceuticals (NASDAQ OPTR) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/8/2013Pedro LichtingerCEOSell148,000$14.69$2,174,120.00View SEC Filing  
11/8/2012Pedro LichtingerCEOBuy11,000$9.08$99,880.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Optimer Pharmaceuticals (NASDAQ OPTR) News Headlines

Source:
DateHeadline
Shire PLC (SHPG) versus Optimer Pharmaceuticals (OPTR) Financial ReviewShire PLC (SHPG) versus Optimer Pharmaceuticals (OPTR) Financial Review
www.americanbankingnews.com - September 19 at 8:10 PM
Financial Contrast: Optimer Pharmaceuticals (OPTR) versus Collegium Pharmaceutical (COLL)Financial Contrast: Optimer Pharmaceuticals (OPTR) versus Collegium Pharmaceutical (COLL)
www.americanbankingnews.com - September 18 at 4:28 AM

SEC Filings

Optimer Pharmaceuticals (NASDAQ:OPTR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Optimer Pharmaceuticals (NASDAQ:OPTR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Optimer Pharmaceuticals (NASDAQ OPTR) Stock Chart for Wednesday, December, 13, 2017

Loading chart…

This page was last updated on 12/13/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.